SUSTAINABILITY

THE pMDI DILEMMA: MANAGING PATIENT NEEDS, HEALTH AND THE PLANET

Nick Smalley discusses the balancing act involved in meeting patients’ therapeutic needs while protecting the planet when it comes to pMDI development.

CREATING VALUE – SUSTAINABLE APPROACHES FOR THE MEDICAL DEVICE INDUSTRY

David Pircher provides insights from a sustainability journey, showcasing what suppliers can contribute and how innovation and partnership support a common vision. The article outlines where the industry stands and why sustainability is a top priority, with concrete examples.

REFORMULATING pMDIS WITH NEXT-GENERATION SUSTAINABLE PROPELLANTS

REFORMULATING pMDIS WITH NEXT-GENERATION SUSTAINABLE PROPELLANTS

Ross Errington and Simon Gardner, discuss sustainability and the reformulation of pMDIs with low-GWP propellants.

TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS

TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS

Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.

PIONEERING PHARMACEUTICAL PACKAGING: A PUSH FOR DECARBONISATION AND CIRCULARITY

Philipp Ludihuser

PIONEERING PHARMACEUTICAL PACKAGING: A PUSH FOR DECARBONISATION AND CIRCULARITY

Philipp Ludihuser and Arne Kloke highlight how SCHOTT Pharma’s collaboration with customers and partners in the pharmaceutical industry reduces the carbon emissions from the production of vials, cartridges, ampoules and syringes, as well as introducing circular solutions to increase resource efficiency.

Interview with Bespak’s Louise Righton & Benedicta Bakpa

Interview with Bespak’s Louise Righton & Benedicta Bakpa

An increasing global incidence of respiratory diseases, such as asthma and COPD, is driving demand for therapies. Simultaneously, greenhouse gas emissions continue to rise, so the pharma industry must consider how to produce much-needed nasally delivered and orally inhaled medicines whilst minimising environmental impact. Louise Righton and Benedicta Bakpa discuss the many different aspects involved in driving sustainability in inhaled drug delivery – and the next steps.

PRIORITISING SUSTAINABILITY IN PHARMA

PRIORITISING SUSTAINABILITY IN PHARMA

Jessica Buday discusses how, in partnership with West Pharmaceutical Services, Corning’s Viridian glass vials are able to simultaneously improve the sustainability and efficiency of pharmaceutical fill-finish lines compared with traditional ISO glass vials, due to their reduced glass volume and proprietary external polymeric coating.

OPPORTUNITY THROUGH INNOVATION – ENVIRONMENTAL AND SOCIAL SUSTAINABILITY IN INJECTION DEVICES

Credence MedSystems

OPPORTUNITY THROUGH INNOVATION – ENVIRONMENTAL AND SOCIAL SUSTAINABILITY IN INJECTION DEVICES

John Merhige and Dan Thayer discuss how the successful implementation of ESG principles in the pharmaceutical sector requires innovation that allows sustainability to be seen as an opportunity rather than a burden. Furthermore, the authors present the case that improving on the social aspect of ESG is just as important as improving on the environmental side.

INTERVIEW with GLENN SVEDBERG

INTERVIEW with GLENN SVEDBERG

Glenn Svedberg engages in a wide-ranging discussion around the role and importance of sustainability in the drug delivery industry, and how Nolato Group has approached implementing this critical aspect of the modern industry landscape. Mr Svedberg considers how sustainability factors play into the relationship between CDMOs like Nolato and pharma companies, the importance of materials and how to drive forward sustainability goals within pharma and drug delivery.

FROM VISION TO VICTORY: BUILDING A HANDS-ON ESG FRAMEWORK

FROM VISION TO VICTORY: BUILDING A HANDS-ON ESG FRAMEWORK

Herman Rusch and Steven van Voorst discuss the steps that IGS GeboJagema has taken to provide its ESG efforts with a robust structure to build on and how doing so has made those efforts more effective and provided the company with clear, meaningful and measurable targets to work towards.

SUSTAINABLE DESIGN FOR HEALTHCARE DEVICES: PATHWAYS TOWARDS NET ZERO

SUSTAINABLE DESIGN FOR HEALTHCARE DEVICES: PATHWAYS TOWARDS NET ZERO

Will Davies and Holly Milston consider sustainable pathways towards circularity in the medical device industry.

INTERVIEW: THE BENEFITS OF BEING AN EARLY ADOPTER OF SUSTAINABILITY PRINCIPLES

INTERVIEW: THE BENEFITS OF BEING AN EARLY ADOPTER OF SUSTAINABILITY PRINCIPLES

Reto Jost and Gabriel Kalbermatter talk exclusively with ONdrugDelivery's Guy Furness, discussing the progress Ypsomed has made in advancing its sustainability agenda, particularly the implementation of its ecodesign guideline, the benefits of being an early adopter of sustainability principles, how YpsoMate 5.5 mL has been designed from the ground up with sustainability in mind and where sustainability considerations currently fit into the wider pharma industry.

DESIGN FOR SUSTAINABILITY – THE CONSIDERATIONS BROUGHT TO LIFE

DESIGN FOR SUSTAINABILITY – THE CONSIDERATIONS BROUGHT TO LIFE

Oli Gould explores the use of lifecycle assessment in product design for sustainability to impact the environment positively.

INTERVIEW with Dora Rio, Head of Sustainability, SHL Medical

INTERVIEW with Dora Rio, Head of Sustainability, SHL Medical

Dora Rio discusses various aspects of SHL's approach to sustainability, including how it interacts with other players up and down the value chain, whether reusable or single-use devices are more sustainable and how SHL addresses sustainability concerns beyond CO₂.

SUSTAINABLE BY DESIGN: DEVELOPING PATIENT- AND PLANET-CENTRIC MEDICAL DEVICES

SUSTAINABLE BY DESIGN: DEVELOPING PATIENT- AND PLANET-CENTRIC MEDICAL DEVICES

Su Osorio, Stephanie Mou and Charlie Dean, explore the delicate balance between patient and planet centricity and propose a user- and planet-centric approach for the development of sustainable medical devices.

TOWARDS A COMPREHENSIVE SUSTAINABILITY STRATEGY

Dr Marie-Christine Klein

TOWARDS A COMPREHENSIVE SUSTAINABILITY STRATEGY

Marie-Christine Klein and Christian Weyler, look at the evolution of the company’s sustainability strategy within its regulatory and economic framework – and what decarbonisation means for the pharmaceutical industry.

SUSTAINABILITY PROGRAMMES: EVERY STEP COUNTS

SUSTAINABILITY PROGRAMMES: EVERY STEP COUNTS

Henryk Badack shares insights into the current state of sustainability in the pharma and biotech industry, how sustainability commitments vary between organisations and what companies can do to develop sustainability strategies that will last.

PCI’S ESG JOURNEY – ESTABLISHING PROCESSES AND DRIVING RESULTS

Gigi Bat-Erdene

PCI Pharma Services

PCI’S ESG JOURNEY – ESTABLISHING PROCESSES AND DRIVING RESULTS

Gigi Bat-Edene discusses the steps that PCI has taken towards realising its environmental, social and governance targets and achieving reductions in its greenhouse gas emissions in the journey towards net zero.

NAVIGATING THE TRANSITION TO SUSTAINABLE MEDICAL PROPELLANTS

Dr Timothy Noakes

NAVIGATING THE TRANSITION TO SUSTAINABLE MEDICAL PROPELLANTS

Timothy Noakes, Sheryl Johnson and Richard Greenhough, discuss the status of the current move from high-global-warming-potential propellants for pressurised metered dose inhalers to more sustainable alternatives.

OPTIMISING LOW-GWP pMDI SPRAYS FOR ENHANCED PERFORMANCE AND SUSTAINABILITY

Dr Benjamin Myatt

Kindeva Drug Delivery

OPTIMISING LOW-GWP pMDI SPRAYS FOR ENHANCED PERFORMANCE AND SUSTAINABILITY

Benjamin Myatt and Daniel Duke explore the low-global-warming-potential propellants available and their implications for the performance of pressurised metered dose inhalers.

CHANGE IS IN THE AIR: THE FUTURE CLIMATE OF INHALED MEDICATION

Pauline Janssen

CHANGE IS IN THE AIR: THE FUTURE CLIMATE OF INHALED MEDICATION

Pauline Janssen, discusses the various available devices for pulmonary delivery of medications, with a deeper dive into the challenges presented by replacing pMDI propellants with high global warming potential with new alternatives, or whether the optimal solution could be phasing out pMDIs in favour of DPIs.

PHARMACEUTICAL INDUSTRY SUSTAINABILITY TARGETS, ONE YEAR ON

Catriona Eldridge

PHARMACEUTICAL INDUSTRY SUSTAINABILITY TARGETS, ONE YEAR ON

Catriona Eldridge, analyses whether the pharmaceutical industry is meeting its targets and doing enough in the fight against climate change.

REUSABLE VERSUS SINGLE-USE DEVICES: TRADE-OFFS IN IMPROVING SUSTAINABILITY

Alastair Willoughby

REUSABLE VERSUS SINGLE-USE DEVICES: TRADE-OFFS IN IMPROVING SUSTAINABILITY

Alastair Willoughby and Prem-Sagar Tank, explore various device trade-offs for both sustainability and cost in reusable injection devices, and consider how this compares with single-use devices.

LEVERAGING AI & BIG DATA FOR ECO-DESIGN COLLABORATION IN PHARMA

LEVERAGING AI & BIG DATA FOR ECO-DESIGN COLLABORATION IN PHARMA

Alissa Monk, Kami Krista, Cédric Montagnetegy and Carole Schanté, explore the potential of artificial intelligence and big data in eco-design with the aim of transforming the pharmaceutical industry towards greater sustainability.

SCALING GLP-1 DRUGS WITHOUT A MOUNTAIN OF WASTE

SCALING GLP-1 DRUGS WITHOUT A MOUNTAIN OF WASTE

Matt Parker, Simon Lyons and Alex Lyness, look at how the continued success of glucagon-like peptide-1 drugs is bringing into focus the need for environmentally sustainable self-injection systems. They discuss whether reloadable autoinjectors could be the way to boost sustainability, lower cost per dose, and match the scale and rate of adoption of these new therapies.

SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES

SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES

Zaid Aqrawe, Philippe Rogueda, Darragh Murnane and Bryan Eng, discuss the opportunity presented by soft mist inhalers as an alternative delivery device to nebulisers for inhaled therapies, contrasting the two device categories across multiple factors.

1
2
3
…
5
Next

Top